CAR T Cell Therapy Market to Reflect Impressive Growth Rate

Increasing incidence of cancer and rising number of patients showing response failure to alternative treatments is expected to foster growth of the global CAR-T cell therapy market. Rising number of adults and children developing cancer is expected to lead to high demand for an effective and reliable therapeutic treatment approach for improvement of quality of patient’s lives. The Cancer Research UK reported that over 14.1 million cancer cases occurred in 2012 across the world. Moreover, according to the Leukemia and Lymphoma Society of Canada, around 22,340 people in Canada were diagnosed with some form of blood cancer, of which 9,000 cases were lymphoma.

Competitive Landscape

Key companies covered as a part of this study includes Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio, Inc. (Celgene Corporation), Sorrento Therapeutics Inc., Mustang Bio, Inc., Aurora Biopharma Inc., Legend Biotech (Genscript Biotech Corporation), Pfizer, Inc. and CARsgen Therapeutics, Ltd.

Moreover, development of new and effective therapy options to cure symptoms of the disease is also a vital factor contributing to growth of CAR-T cell therapy market. In 2017, the U.S. Food and Drug Administration approved two CAR-T cell therapies Kymriah and Yescarta for children and adult lymphoblastic leukemia and advanced lymphoma in adults, respectively. This is expected to aid in growth of the market over the forecast period.

Read more at: https://www.openpr.com/news/1493481/CAR-T-Cell-Therapy-Market-to-Reflect-Impressive-Growth-Rate-Top-Players-Novartis-International-AG-Kite-Pharma-Inc-Gilead-Sciences-Inc-Juno-Therapeutics-Celgene-Corporation-Bluebird-Bio-Inc-Celgene-Corporation.html